BLUE - bluebird bio, Inc.

QQQ $ 592.57 $ 0.00 (0 %)

DIA $ 456.06 $ 0.00 (0 %)

SPY $ 653.88 $ 0.00 (0 %)

TLT $ 91.47 $ 0.00 (0 %)

GLD $ 399.29 $ 0.00 (0 %)

Previous Close

$ 4.97

Open

Bid

-- x --

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 3.20 - $ 28.60

Volume

1,245,197

Average Volume

Market Cap

48.67M

Beta (5Y Monthly)

$ 1.02

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2025	03-31-2025	10-Q
2	03-27-2025	12-31-2024	10-K
3	11-14-2024	09-30-2024	10-Q
4	09-27-2024	06-30-2024	10-Q
5	09-13-2024	03-31-2024	10-Q
6	09-13-2024	12-31-2023	10-K
7	11-07-2023	09-30-2023	10-Q
8	08-08-2023	06-30-2023	10-Q
9	05-09-2023	03-31-2023	10-Q
10	03-29-2023	12-31-2022	10-K
11	11-07-2022	09-30-2022	10-Q
12	08-04-2022	06-30-2022	10-Q
13	05-09-2022	03-31-2022	10-Q
14	03-04-2022	12-31-2021	10-K
15	11-05-2021	09-30-2021	10-Q
16	08-09-2021	06-30-2021	10-Q
17	05-05-2021	03-31-2021	10-Q
18	02-23-2021	12-31-2020	10-K
19	11-04-2020	09-30-2020	10-Q
20	08-05-2020	06-30-2020	10-Q
21	05-11-2020	03-31-2020	10-Q
22	02-18-2020	12-31-2019	10-K
23	10-31-2019	09-30-2019	10-Q
24	08-01-2019	06-30-2019	10-Q
25	05-03-2019	03-31-2019	10-Q
26	02-21-2019	12-31-2018	10-K
27	11-01-2018	09-30-2018	10-Q
28	08-02-2018	06-30-2018	10-Q
29	05-02-2018	03-31-2018	10-Q
30	02-21-2018	12-31-2017	10-K
31	11-01-2017	09-30-2017	10-Q
32	08-02-2017	06-30-2017	10-Q
33	05-03-2017	03-31-2017	10-Q
34	02-22-2017	12-31-2016	10-K
35	11-02-2016	09-30-2016	10-Q
36	08-03-2016	06-30-2016	10-Q
37	05-04-2016	03-31-2016	10-Q
38	02-25-2016	12-31-2015	10-K
39	11-05-2015	09-30-2015	10-Q
40	08-07-2015	06-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Carlyle And SK Capital's Tender Offer For ...
05/30/2025 12:36:31

All conditions of the Offer have been satisfied and the parties expect to consummate the acquisition on June 2, 2025Carlyle (NA...

Carlyle And SK Capital Amend Agreement To ...
05/16/2025 20:37:13

Stockholders that have previously tendered their shares must re-tender their sharesStockholders may elect to receive either $3....

bluebird-bio-shareholders-get-new-all-cash-offer-from-private-equity

Bluebird Bio Shareholders Get New All-Cash...
05/14/2025 17:27:17

Bluebird Bio revised its agreement with Carlyle and SK Capital, adding a $5 per share cash option for stockholders ahead of dea...

12 Health Care Stocks Moving In Wednesday'...
05/14/2025 17:06:23

Carlyle, SK Capital Partners And bluebird ...
05/14/2025 12:33:54

bluebird bio, Carlyle, SK Capital And Beac...
05/05/2025 20:06:21

bluebird Board of Directors unanimously supports the transaction as the only viable option for stockholders to receive consider...

bluebird bio Announces That After Three We...
04/16/2025 12:07:41

bluebird Board reaffirms unanimous recommendation in support of transaction with Carlyle and SK Capital and recommends all stoc...

Carlyle, SK Capital Partners, And Beacon P...
04/16/2025 11:39:22

deal-dispatch-us-ma-is-quiet-but-abroad-volume-is-spiking

Deal Dispatch: US M&A Is Quiet, But Abroad...
04/04/2025 19:07:59

BofA predicted a friendlier FTC under Trump. They were wrong. Deal activity was virtually flat in Q1. But it's a U.S. problem.

bluebird-shares-are-up-today-whats-going-on

BlueBird Shares Are Up Today: What's Going...
03/31/2025 19:49:40

Bluebird Bio Inc. (NASDAQ: BLUE) shares are trading higher Monday after the company received an unsolicited takeover offer from...

12-health-care-stocks-moving-in-mondays-intraday-session

12 Health Care Stocks Moving In Monday's I...
03/31/2025 17:05:39

gene-therapy-focused-bluebird-bio-receives-rival-takeover-offer-stock-jumps

Gene Therapy-Focused Bluebird Bio Receives...
03/31/2025 15:24:14

Bluebird Bio reviews an unsolicited $4.50 per share bid from Ayrmid after agreeing to a $3.00 per share buyout with Carlyle and...

Barclays Maintains Overweight on bluebird ...
03/31/2025 14:43:00

Barclays analyst Gena Wang maintains bluebird bio (NASDAQ:BLUE) with a Overweight and lowers the price target from $40 to $8.

Market-Moving News for March 31st
03/31/2025 11:51:12

QSG: 50% | QuantaSing Group Expands Into Pop Toys Market with Strategic Acquisition Of Letsvan, Tapping High-Growth Consumer Go...

12-health-care-stocks-moving-in-fridays-after-market-session

12 Health Care Stocks Moving In Friday's A...
03/28/2025 21:05:46

bluebird bio Confirms Receipt Of An Unsoli...
03/28/2025 20:16:23

bluebird bio, Inc. (NASDAQ:BLUE) ("bluebird") today confirmed it has received an unsolicited non-binding written propos...

'Bluebird Gets New M&A Bid, Seeking To Top...
03/28/2025 19:56:33

https://endpts.com/bluebird-gets-new-ma-bid-seeking-to-top-private-equity-offer/

Watching bluebird bio; Traders Circulate U...
03/28/2025 19:55:20

bristol-myers-squibb-scoops-up-its-blood-cancer-drug-partner-2seventy-bio-in-286-million-deal

Bristol Myers Squibb Scoops Up Its Blood C...
03/11/2025 14:17:35

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last cl...

JP Morgan Upgrades bluebird bio to Neutral
02/24/2025 12:00:40

JP Morgan analyst Eric Joseph upgrades bluebird bio (NASDAQ:BLUE) from Underweight to Neutral.